LAURA REHAK

Dr. LAURA REHAK

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LRLAURA REHAK
LAURA REHAK
LGLaura Giurato
Laura Giurato
Marco MeloniMarco Meloni
Marco Meloni
APAndrea Panunzi
Andrea Panunzi
GMGiada Maria Manti
Giada Maria Manti
Luigi UccioliLuigi Uccioli
Luigi Uccioli
Monocytes and lymphocytes play a key role in physiologic wound healing and might be involved in the impaired mechanisms observed in diabetes. Skin wound macrophages are represented by tissue resident macrophages and infiltrating peripheral blood recruited monocytes which play a leading role during the inflammatory phase of wound repair. The impaired transition of diabetic wound macrophages from pro-inflammatory M1 phenotypes to anti-inflammatory pro-regenerative M2 phenotypes might represent a key issue for impaired diabetic wound healing. This review will focus on the role of immune system cells in normal skin and diabetic wound repair. Furthermore, it will give an insight into therapy able to immuno-modulate wound healing processes toward to a regenerative anti-inflammatory fashion. Different approaches, such as cell therapy, exosome, and dermal substitute able to promote the M1 to M2 switch and able to positively influence healing processes in chronic wounds will be discussed.

Verified
Journal Article
Open access
PDF file
PSPasqualina Scala
Pasqualina Scala
LRLAURA REHAK
LAURA REHAK
VGValentina Giudice
Valentina Giudice
ECElena Ciaglia
Elena Ciaglia
Annibale Alessandro PucaAnnibale Alessandro Puca
Annibale Alessandro Puca
Nicola MaffulliNicola Maffulli
Nicola Maffulli
In severe muscle injury, skeletal muscle tissue structure and functionality can be repaired through the involvement of several cell types, such as muscle stem cells, and innate immune responses. However, the exact mechanisms behind muscle tissue regeneration, homeostasis, and plasticity are still under investigation, and the discovery of pathways and cell types involved in muscle repair can open the way for novel therapeutic approaches, such as cell-based therapies involving stem cells and peripheral blood mononucleate cells. Indeed, peripheral cell infusions are a new therapy for muscle healing, likely because autologous peripheral blood infusion at the site of injury might enhance innate immune responses, especially those driven by macrophages. In this review, we summarize current knowledge on functions of stem cells and macrophages in skeletal muscle repairs and their roles as components of a promising cell-based therapies for muscle repair and regeneration.

15 January 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
BSBenjamin Swartzwelter
Benjamin Swartzwelter
AVAlessandro Verde
Alessandro Verde
LRLAURA REHAK
LAURA REHAK
MMMariusz Madej
Mariusz Madej
VPVictor Puntes
Victor Puntes
PIPaola Italiani
Paola Italiani
Understanding the modes of interaction between human monocytes/macrophages and engineered nanoparticles is the basis for assessing particle safety, in terms of activation of innate/inflammatory reactions, and their possible exploitation for medical applications. In vitro assessment of nanoparticle-macrophage interaction allows for examining the response of primary human cells, but the conventional 2D cultures do not reproduce the three-dimensional spacing of a tissue and the interaction of macrophages with the extracellular tissue matrix, conditions that shape macrophage recognition capacity and reactivity. Here, we have compared traditional 2D cultures with cultures on a 3D collagen matrix for evaluating the capacity gold nanoparticles to induce monocyte activation and subsequent innate memory in human blood monocytes in comparison to bacterial LPS. Results show that monocytes react to stimuli almost in the same way in 2D and 3D cultures in terms of production of TNFα and IL-6, but that notable differences are found when IL-8 and IL-1Ra are examined, in particular in the recall/memory response of primed cells to a second stimulation, with the 3D cultures showing cell activation and memory effects of nanoparticles better. In addition, the response variations in monocytes/macrophages from different donors point towards a personalized assessment of the nanoparticle effects on macrophage activation.

8 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MBMichela Bonanni
Michela Bonanni
LRLAURA REHAK
LAURA REHAK
GMGianluca Massaro
Gianluca Massaro
DBdaniela benedetto
daniela benedetto
AMAndrea Matteucci
Andrea Matteucci
Sangiorgi Giuseppe MassimoSangiorgi Giuseppe Massimo
Sangiorgi Giuseppe Massimo
About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED.

28 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LRLAURA REHAK
LAURA REHAK
LGLaura Giurato
Laura Giurato
MMMatteo Monami
Matteo Monami
Marco MeloniMarco Meloni
Marco Meloni
ASAlessia Scatena
Alessia Scatena
Luigi UccioliLuigi Uccioli
Luigi Uccioli
Chronic limb-threatening ischemia (CLTI), the most advanced form of peripheral arterial disease (PAD), is the comorbidity primarily responsible for major lower-limb amputations, particularly for diabetic patients. Autologous cell therapy has been the focus of efforts over the past 20 years to create non-interventional therapeutic options for no-option CLTI to improve limb perfusion and wound healing. Among the different available techniques, peripheral blood mononuclear cells (PBMNC) appear to be the most promising autologous cell therapy due to physio-pathological considerations and clinical evidence, which will be discussed in this review. A meta-analysis of six clinical studies, including 256 diabetic patients treated with naive, fresh PBMNC produced via a selective filtration point-of-care device, was conducted. PBMNC was associated with a mean yearly amputation rate of 15.7%, a mean healing rate of 62%, and a time to healing of 208.6 ± 136.5 days. Moreover, an increase in TcPO2 and a reduction in pain were observed. All-cause mortality, with a mean rate of 22.2% and a yearly mortality rate of 18.8%, was reported. No serious adverse events were reported. Finally, some practical and financial considerations are provided, which point to the therapy’s recommendation as the first line of treatment for this particular and crucial patient group.

1 January 2026 in BIOCELL
Verified
Journal Article
Open access
PDF file
AMAndrea De Matthaeis
Andrea De Matthaeis
LRLAURA REHAK
LAURA REHAK
MBMaria Bianchi
Maria Bianchi
RPRossana Putzulu
Rossana Putzulu
NPNicola Piccirillo
Nicola Piccirillo
GMGiulio Maccauro
Giulio Maccauro
For over two decades, mesenchymal stem cells (MSCs) have been recognised as the cornerstone of orthobiologic treatments for musculoskeletal diseases. However, clinical evidence increasingly indicates that MSC engraftment in inflamed tissues is minimal and transient, with effects mainly driven by paracrine and immunomodulatory mechanisms induced by macrophage efferocytosis. This evolving paradigm emphasises the immune system as the central orchestrator of tissue repair. Peripheral blood mononuclear cells (PBMNCs) have emerged as potent effectors of regenerative inflammation, mediating apoptotic cell clearance through efferocytosis, facilitating the transition of macrophages from pro-inflammatory (M1) to reparative (M2) phenotypes, and releasing angiogenic and trophic factors that support vascularisation, matrix remodelling, and functional restoration. Clinical studies in critical limb ischemia and diabetic foot provide compelling evidence that autologous PBMNC implantation yields meaningful outcomes in conditions refractory to conventional therapies. Concurrently, platelet-rich plasma (PRP), long regarded as a reservoir of growth factors, is now recognised as a potent recruiter of PBMNCs, where platelet-derived chemokines, such as Monocyte Chemoattractant Protein-1, (MCP-1), Regulated upon Activation, Normal T Cell Expressed and Secreted (RANTES), and Stromal cell-derived factor-1 (SDF-1), establish chemotactic gradients that attract immune cells to injury sites. Neutrophil-depleted, monocyte-enriched PRP formulations demonstrate therapeutic promise in the treatment of osteoarthritis, tendinopathy, and muscle injury. This review consolidates the current scientific rationale and clinical evidence supporting an immune-centric framework, in which PBMNCs, delivered alone or enriched within PRP, constitute a promising next-generation of orthobiologic therapies for musculoskeletal regeneration.